| Literature DB >> 31803017 |
Lavrentii G Danilov1, Andrew G Matveenko1, Varvara E Ryzhkova1, Mikhail V Belousov1,2, Olga I Poleshchuk1, Daria V Likholetova1, Petr A Sokolov3, Nina A Kasyanenko3, Andrey V Kajava4,5, Galina A Zhouravleva1,6, Stanislav A Bondarev1,6.
Abstract
A number of [PSI +]-no-more (PNM) mutations, eliminating [PSI +] prion, were previously described in SUP35. In this study, we designed and analyzed a new PNM mutation based on the parallel in-register β-structure of Sup35 prion fibrils suggested by the known experimental data. In such an arrangement, substitution of non-charged residues by charged ones may destabilize the fibril structure. We introduced Q33K/A34K amino acid substitutions into the Sup35 protein, corresponding allele was called sup35-M0. The mutagenized residues were chosen based on ArchCandy in silico prediction of high inhibitory effect on the amyloidogenic potential of Sup35. The experiments confirmed that Sup35-M0 leads to the elimination of [PSI +] with high efficiency. Our data suggested that the elimination of the [PSI +] prion is associated with the decreased aggregation properties of the protein. The new mutation can induce the prion with very low efficiency and is able to propagate only weak [PSI +] prion variants. We also showed that Sup35-M0 protein co-aggregates with the wild-type Sup35 in vivo. Moreover, our data confirmed the utility of the strategy of substitution of non-charged residues by charged ones to design new mutations to inhibit a prion formation.Entities:
Keywords: ArchCandy; SUP35 mutation; Saccharomyces cerevisiae; [PSI+]; amyloid; prion; superpleated-β-structure
Year: 2019 PMID: 31803017 PMCID: PMC6877606 DOI: 10.3389/fnmol.2019.00274
Source DB: PubMed Journal: Front Mol Neurosci ISSN: 1662-5099 Impact factor: 5.639
Strains of S. cerevisiae used in this study.
| 7A-D832 | Bondarev et al., | |
| 10-7A-D832 | Bondarev et al., | |
| 2-OT56 | Matveenko et al., | |
| GT159 | Chernoff et al., | |
| GT671 | Gift from Y.O. Chernoff | |
| U-GT671 | This study | |
| 12-D1682 | This study | |
| 74-D694 | Derkatch et al., | |
| P-74-D694 | Drozdova et al., |
Plasmids used in this study.
| pRSU1 | Volkov et al., | |
| pRSU1-sup35-M0 | This study | |
| pRSU2 | Volkov et al., | |
| pRSU2-sup35-M0 | This study | |
| pRS316CUP-NM-GFP | Serio et al., | |
| pRS316CUP-NM-M0-GFP | This study | |
| pET-20b-SUP35NM-His6 | Allen et al., | |
| pET-20b-SUP35NM-M0-His6 | This study | |
| pRS315CUP-NM-GFP | This study | |
| pRS315CUP-NM-M0-GFP | This study | |
| pRS315 | Sikorski and Hieter, | |
| pRS315CG | This study | |
| pR16CUP-NM-yTagRFP-T | This study | |
| pIM35 | Malcova et al., |
For each plasmid, the following characteristics are indicated: yeast selective marker, (“-” — the absence of a yeast selective marker), bacterial selective marker, promoter of the inserted gene, gene of interest. All yeast plasmids in the table are centromeric.
Figure 1Substitutions Q33K/A34K within N-domain of Sup35 decrease the amyloidogenic potential of the protein. The ArchCandy program (Ahmed et al., 2015) was used to predict amyloidogenic properties. Cumulative scores (sum of β-arch scores counted for each amino acid residue) are presented on the plot. WT — wild-type protein; G58D, Q33K/A34K, Y46K/Q47K, and Q61K/Q62K substitutions that correspond to mutations PNM2, sup35-M0, -M1, and -M2, respectively.
Figure 2sup35-M0 efficiently and irreversibly eliminates [PSI+] prion. (A) The phenotype of strains with different combinations of SUP35 and sup35-M0 alleles in [PSI+] and [psi–] strains on 1/4 YEPD is shown (images were taken after 4 days of incubation). Transformants bearing two plasmids with two wild-type alleles or combination of sup35-M0 and SUP35 are presented on the panel “WT/mut” (at least 16 transformants were analyzed). The phenotype of cells after the plasmid loss is shown on panel “mut”. Finally, sup35-M0 (or SUP35 as a control) were replaced with SUP35 by the reverse plasmid shuffling, phenotype of obtained strains is presented on panel “WT after mut.” (B) The sup35-M0 allele leads to the elimination of Sup35 aggregates according to SDD-AGE results. Antibodies against Sup35 were used for Western Blotting. (C) Result of Western Blot hybridization after SDS-PAGE analysis of protein lysates from the [psi–] strain with mutant or wild-type allele of SUP35 with anti-Sup35 and anti-Tub1 antibodies. (D) The densitometry analysis of Sup35 protein level (ten replicates) revealed no difference in Sup35 protein level in strains with sup35-M0 compared to SUP35. (E) [PSI+] transmission from the wild-type to the indicated sup35 allele. Fraction of cells that retained the prion after loss of the wild-type allele is shown on graph. (F) [PSI+] loss induced by transient expression of the sup35 alleles and PNM2 mutation. Fraction of cells that have lost the prion after the loss of sup35 allele is shown. **p-value < 0.01 and ***p-value < 0.001 according to Fisher's exact test.
Figure 3Sup35NM-M0 forms infectious amyloid aggregates. (A) Result of Coomassie staining of the gel after SDS-PAGE analysis of Sup35 fibrils formed in vitro. Sup35-M0 forms SDS-resistant aggregates similar to wild-type Sup35. (B) AFM and TEM images of fibrils formed by Sup35NM or Sup35NM-M0. (C) Phenotype of [psi–][pin–] strain (2-OT56) transformed with fibrillar or monomeric proteins on 1/4 YEPD (16 independent transformants are shown for each case, images were taken after 5 days of incubation). The appearance of [PSI+] phenotype (white color) after protein transformation suggested infectious properties of the aggregates.
Figure 4sup35-M0 can induce and propagate [PSI+] prion but with low efficiency. (A) Frequencies of [PSI+] induction in the [psi–][PIN+] 7A-D832 (A) and 12-D1682 (B) cells upon overexpression of SUP35NM-GFP (WT) or sup35NM-M0-GFP (M0) in the presence of wild-type or mutant allele of SUP35. Overproduction of GFP hereafter was used as a negative control. All constructions were under control of CUP1 promoter, CuSO4 was used for the 24 h induction. All experiments were repeated six times. Our results demonstrated that the mutation has a dramatically lower potential to induce [PSI+] prion than SUP35 (***p-value < 0.001 according to Fisher's exact test). The “Allele” designates allele of full-length SUP35 present in cells. (C) The cells tested on panel A were analyzed with the fluorescence microscopy (scale bar equals 5 μm). Various types of prion aggregates (dots, rings, and ribbons) were detected in the presence of both alleles (SUP35 and sup35-M0). (D) Results of Western Blot hybridization after SDS-PAGE analysis of protein lysates of strains used for [PSI+] induction. (E) Densitometry analysis of the Western Blotting. The level of N-terminal domain of Sup35 fused to GFP was normalized to the full-length Sup35-M0 which is unchanged in cells with wild-type and mutant sup35 allele according to the results presented on the Figure 2 (**p-value < 0.01 according to Mann-Whitney U-test). (F) The nonsense suppressor phenotype of several [PSI+] variants induced in presence of SUP35 or sup35-M0 in the 12-D1682 strain. Ten independent isolates are shown for each case. Cells were grown for 4 days on 1/4 YEPD and 5 days on SC-Ade. (G) The results of SDD-AGE analysis of protein lysates of typical [PSI+] variants induced in the presence of sup35-M0, antibodies against Sup35 were used for Western Blotting.
Figure 5The Sup35-M0 protein can incorporate into fibrils of wild-type protein in vivo. (A) [psi–][PIN+] (74-D694) and [PSI+][PIN+] (P-74-D694) yeast strains were transformed with the plasmids for overproduction of Sup35NM-yTagRFP-T, in combination with either Sup35NM-GFP or Sup35NM-M0-GFP. We observed that the aggregates of Sup35NM and Sup35NM-M0 colocalize in [PSI+], as well as in [psi–] cells (scale bar equals 10 μm). (B) The transformants of [psi–][PIN+] (7A-D832) and [PSI+][PIN+] (10-7A-D832) with overproduced Sup35NM-GFP (WT), or Sup35NM-M0-GFP (M0) were analyzed with fluorescence microscopy (scale bar equals 5 μm). We detected foci of both proteins only in [PSI+], but not in [psi–], strain, which indicates inclusion of the proteins into existing aggregates. (C) The result of SDS-PAGE with boiled gel for strains from the panel B was shown. The “Allele” designates allele of full-length SUP35 present in cells. The Sup35NM-GFP (WT) and Sup35NM-M0-GFP (M0) proteins can incorporate into the existing prion aggregates upon transient overproduction in [PSI+] strain (both are detected in a fraction of aggregates). (D) Production of Sup35NM-M0-GFP does not affect the number of propagons. The cells from the panel B were used to calculate number of propagons before and after mild overproduction of Sup35NM-GFP or Sup35NM-M0-GFP; 25 μM CuSO4 was used for the induction. (E) Cells with overproduction of Sup35NM-TagRFP-T together with Sup35-NM-M0-GFP or Sup35NM-GFP were analyzed for prion toxicity. Cells were plated in 10-fold serial dilutions and grown for 2 days on SC-LeuUra + Cu2+ or YEPD and 4 days on SC-UraLeu. TagRFP-T production was used as a control; vector — pRS315.
Figure 6The sup35-M0 mutation destabilizes different [PSI+] variants. (A) The suppressor phenotype of the obtained [PSI+] variants (designated by numbers 1-7). [PSI+] designates the 10-7A-D832 strain. Cells were plated in 10-fold serial dilutions and grown for 3 days on YEPD and 5 days on SC-Ade. (B) The comparison of Sup35 aggregate size in strains from the panel A. [psi–] is the 12-D1682 strain. (C) The suppressor phenotype of the same strains after the replacement of SUP35 by sup35-M0. Cells were grown for 3 days on YEPD or 1/4 YEPD and 7 days on SC-Ade.